Integra Lifesciences (IL3) Stock Statistics & Valuation Metrics

Integra Lifesciences has a market cap or net worth of $811.58M. The enterprise value is €2.84B.

Integra Lifesciences has 77,892,110 shares outstanding. The number of shares has decreased by -2.65% in one year.

Integra Lifesciences’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 0.29%.

The current PE Ratio of Integra Lifesciences is ―. Integra Lifesciences’s PEG ratio is 2.28.

In the last 12 months, Integra Lifesciences had revenue of 1.61B and earned -6.94M in profits. Earnings per share was -0.09.

In the last 12 months, operating cash flow was 89.31M and capital expenditures -39.55M, giving a free cash flow of 69.90M billion.

Integra Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―

Integra Lifesciences upcoming earnings date is Feb 25, 2026, Before Open (Confirmed).

Integra Lifesciences as a current ratio of 1.17, with Debt / Equity ratio of 20.58%

In the past 12 months, Integra Lifesciences has paid -11.29M in taxes.

Integra Lifesciences EV to EBITDA ratio is 18.03, with an EV/FCF ratio of 139.59.

Integra Lifesciences has $267.88M in cash and marketable securities with $213.51M in debt, giving a net cash position of $54.37M billion.

Gross margin is 54.53%, with operating margin of 1.76%, and net profit margin of -0.43%.

The average price target for Integra Lifesciences is $10.58, which is 11.43% higher than the current price. The consensus rating is Strong Sell